comparemela.com

Latest Breaking News On - Junshi biosciences zhi li - Page 1 : comparemela.com

Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line

SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS)

United statesPatricia keeganRuihua xuRosh diasMcdavid stilwellJunshi biosciencesCoherus biosciencesJunshi biosciences zhi liBrian grancagnoloExchange commission onIr teamCoherus biosciences incDrug administrationSun yat sen university cancer centerShanghai junshi biosciences co ltdExchange commission

Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study

- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC -

United statesSan franciscoPatricia keeganDenny lanfearCoherus biosciencesSheng yaoEli lillyRuihua xuMcdavid stilwellJunshi biosciencesJunshi biosciences zhi liInstitute of microbiology chinese academyCoherus biosciences incDrug administrationJunshi biosciences contact information ir teamSun yat sen university cancer center

vimarsana © 2020. All Rights Reserved.